|
Contents |
|
|
|
|
|
|
Advanced
Cancer
|
 
|
|
|
S
Ablett, V Batra, M Dugan, EJ Estlin, R Gowing, J Kohler, L Lashford, I
Lewis, H MacDowell, B Moreland, AD Pearson, CR Pinkerton, L Price, P
Reidenberg, P Statkevich, D Walker
Phase I study of temozolomide in pediatric
patients with advanced cancer
ASCO Proceedings, 1996 Annual Meeting, Abstract
|
|
V
Batra, M Dugan, SL Gerson, J Haaga, L Liu, S Majka, P Reidenberg, J
Schupp, TP Spiro, P Statkevich, JK Willson
Rapid
depletion of O6-alkylguanine DNA alkyltransferase with twice daily oral
temozolomide (SCH 52365) in patients with advanced cancer
ASCO
Proceedings, 1996 Annual Meeting,
Abstract
|
|
D
Cutler, Louis Denis, R Drengler, S Eckhardt, Jose Figueroa, C Geyer, L Reyderman,
Eric Rowinsky, A Tolcher, Daniel Von Hoff
Protracted
Cyclic Administration of Temozolomide Is Feasible; a Phase I, Pharmacokinetic
and Pharmacodynamic Study
ASCO Proccedings, 2000
Annual Meeting, Abstract No. 868
|
|
D
Cutler, Louis Denis, R Drengler, S Eckhardt, Jose Figueroa, C Geyer, L
Reyderman, Eric Rowinsky, A Tolcher, Daniel Von Hoff
Protracted Daily Administration of Temozolomide
Is Feasible: A Phase I and Pharmacokinetic - Pharmacodynamic Study
ASCO Proccedings, 2000
Annual Meeting, Abstract No. 786
|
|
Dhodapkar
M, Rubin J, Reid JM, Burch PA, Pitot HC, Buckner JC, Ames MM, Suman VJ.
Phase
I trial of temozolomide (NSC 362856) in patients with advanced cancer
Clin Cancer Res 1997 Jul;3(7):1093-100
|
|
Estlin EJ, Lashford L, Ablett S, Price L, Gowing R, Gholkar A,
Kohler J, Lewis IJ, Morland B, Pinkerton CR, Stevens MC, Mott M, Stevens
R, Newell DR, Walker D, Dicks-Mireaux C, McDowell H, Reidenberg P,
Statkevich P, Marco A, Batra V, Dugan M, Pearson AD.
Phase
I study of temozolomide in paediatric patients with advanced cancer.
United Kingdom Children's Cancer Study Group
Br J Cancer 1998
Sep;78(5):652-61
|
|
Birgit
Geoerger, Gilles Vassal, Francois Doz, Marie A Raquin, Didier Frappaz,
Pascal Chastagner, Herve Rubie, Jean-Claude Gentet, John O'Quigley, Kamal
Djazouli, Geoffrey P Margison, Francois Pein
Dose-finding
study and O6-alkyltransferase depletion of cisplatin combined with
temozolomide in pediatric solid malignancies
ASCO Proceedings, 2002
Annual Meeting, Abstract No. 424
|
|
Rakesh
Goel, Stanley Gertler, David J Stewart, Scott Laurie, Glenwood Goss,
Neil Reaume, Joanne Roach, Deborah Bedard, Angela Rodgers, David Cutler
Phase I study of temozolomide in conjunction with
gemcitabine
ASCO Proceedings, 2002 Annual Meeting, Abstract No. 2162
|
|
SF
Jones, FA Greco, JD Hainsworth, VG Gian, FT Miranda, JF Patton, NT
Willcutt, MN Baker, HA Burris III
A Phase I Trial of Chronic Oral Fixed Dose
Temozolomide
ASCO Proceedings, 2001
Annual Meeting, Abstract No. 466
|
|
Newlands
ES, Blackledge G, Slack JA, Goddard C, Brindley CJ, Holden L, Stevens MF.
Phase I clinical trial of mitozolomide.
Cancer Treat Rep.
1985 Jul-Aug;69(7-8):801-5.
.JPG)
Abstract
| .gif) Related
articles
|
|
Newlands
ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, Stuart NS,
Quarterman CP, Hoffman R, Stevens MF, Brampton MH, et al.
Phase I trial of temozolomide (CCRG 81045:
M&B 39831: NSC 362856)
Br J Cancer 1992 Feb;65(2):287-91
Abstract
| .png)
Reprint
| Related
articles
|
|
|
Ependymoma |
|
|
|
Riccardo
Soffietti, Alessandra Costanza, Mauro Nobile, Roberta Ruda', Roberto
Mutani
Temozolomide for recurrent ependymomas of the
adult
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002. Abstract
No.
2078
|
|
|
Gliomas
(Low-Grade) |
|
|
|
Charlotte
Abson, Susan Ashley, Michael Brada, Juliet Britton, Frances Hines,
Louis Viviers
A
Phase II Trial of Primary Chemotherapy with Temozolomide in Patients with
Low-Grade Cerebral Gliomas
ASCO Proceedings, 2000 Annual Meeting, Abstract No. 648
|
|
|
Blonski M, Taillandier L, Herbet G, Maldonado IL, Beauchesne P, Fabbro M,
Campello C, Gozé C, Rigau V, Moritz-Gasser S, Kerr C, Rudŕ R, Soffietti R,
Bauchet L, Duffau H.
Combination of neoadjuvant chemotherapy followed by surgical resection as
a new strategy for WHO grade II gliomas: a study of cognitive status and
quality of life.
J Neurooncol.
2011 Jul 22. [Epub ahead of print]
Abstract |
Related articles
|
|
M. Brada, L. Viviers,
C. Abson, F. Hines, J. Britton, S.
Ashley, S. Sardell, D. Traish, A.
Gonsalves, P. Wilkins and C. Westbury
Phase II study of primary
temozolomide chemotherapy in patients with WHO grade II gliomas
Annals of Oncology 14:1715-1721, 2003. (PDF Full Text)
|
|
Paul Brown, Jan Buckner
Temozolomide: Too Early for Definitive Conclusions
Journal of Clinical Oncology, Vol 21, CNO 19 (October 1),
2003: 3710. (Reference+)
|
|
|
Chamberlain MC.
Temozolomide for recurrent low-grade spinal cord gliomas in adults
Cancer. 2008 Jul 9. [Epub
ahead of print]
Abstract
|
|
Hugues Duffau, Luc Taillandier
and Laurent Capelle
Radical
surgery after chemotherapy: a new therapeutic strategy to envision in grade
II glioma
Journal of Neuro-Oncology,
Vol 80, No 2, Nov 2006, Pages 171-176, DOI: 10.1007/s11060-006-9168-3. Published
online: 28 April 2006
|
|
K. Hoang-Xuan, L. Capelle, M.
Kujas, S. Taillibert, H. Duffau, J.
Lejeune, M. Polivka, E. Criničre, Y.
Marie, K. Mokhtari, A.F. Carpentier, F.
Laigle, J.M. Simon, P. Cornu, P.
Broët, M. Sanson, J.Y. Delattre
Temozolomide As Initial Treatment for Adults With Low-Grade
Oligodendrogliomas or Oligoastrocytomas and Correlation With
Chromosome 1p Deletions
Journal of Clinical Oncology, Vol 22, No 15 (August 1), 2004:
pp. 3133-3138.
|
|
|
Kesari
S, Schiff D, Drappatz J, Lafrankie D, Doherty L, Macklin EA, Muzikansky A,
Santagata S, Ligon KL, Norden AD, Ciampa A, Bradshaw J, Levy B, Radakovic G,
Ramakrishna N, Black PM, Wen PY
Phase
II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Clin
Cancer Res. 2009 Jan 1;15(1):330-337
Abstract
|
|
|
Lashkari HP, Saso S, Moreno L, Athanasiou T, Zacharoulis S.
Using
different schedules of Temozolomide to treat low grade gliomas: systematic
review of their efficacy and toxicity.
J Neurooncol.
2011 Jul 5. [Epub ahead of print]
Abstract |
Related articles
|
|
A. Pace, A. Vidiri,
E. Galič, M. Carosi, S. Telera, A.
M. Cianciulli, P. Canalini, D. Giannarelli,
B. Jandolo and C. M. Carapella
Temozolomide chemotherapy for
progressive low-grade glioma: clinical benefits and radiological response
Annals of Oncology 14:1722-1726, December 2003.
|
|
Nader Pouratian, Jaime Gasco,
Jonathan H. Sherman, Mark E. Shaffrey and David Schiff
Toxicity and efficacy of
protracted low dose temozolomide for the treatment of low grade gliomas
J Neurooncol. 2006 Nov 3; [Epub
ahead of print]. DOI: 10.1007/s11060-006-9280-4
|
|
Jennifer A. Quinn,
David A. Reardon, Allan H. Friedman, Jeremy
N. Rich, John H. Sampson, James M.
Provenzale, Roger E. McLendon, Sridharan
Gururangan, Darell D. Bigner, James E.
Herndon, II, Nicholas Avgeropoulos, Jonathan
Finlay, Sandra Tourt-Uhlig, Mary Lou
Affronti, Brandon Evans, Valerie
Stafford-Fox, Sara Zaknoen, Henry S.
Friedman
Phase II Trial of Temozolomide in
Patients With Progressive Low-Grade Glioma
Journal of Clinical Oncology, Vol 21, Issue 4 (February 15),
2003: 646-651. (Abstract+)
|
|
Nader Pouratian, Jaime Gasco,
Jonathan H. Sherman, Mark E. Shaffrey and David Schiff
Toxicity and efficacy of
protracted low dose temozolomide for the treatment of low grade gliomas
J Neurooncol. 2006 Nov 3; [Epub
ahead of print]. DOI: 10.1007/s11060-006-9280-4
|
|
|
Schiff
D.
Temozolomide and Radiation in Low-Grade and Anaplastic Gliomas:
Temoradiation.
Cancer Invest.
2007 Oct 18;:1-9 [Epub ahead of print]
Abstract
|
|
|
Spena G, Garbossa D, Barletta L, Prevost C, Versari P.
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a
useful strategy to maximize surgical resection
Neurol Med Chir (Tokyo). 2010;50(5):410-3. Release Date: 2010 May 25
Abstract |
Reprint
|
|
|
Tosoni
A, Franceschi E, Ermani M, Bertorelle R, Bonaldi L, Blatt V, Brandes AA
Temozolomide three weeks on and one week off as first line therapy for
patients with recurrent or progressive low grade gliomas
J Neurooncol.
2008 Apr 23; [Epub ahead of print]
Abstract
|
|
P. Y. Wen, D. Schiff,
L. Doherty, D. Gigas, A. Musikansky,
J. Bradshaw, B. Levy, S. Kesari, N.
Ramakrishna, E. Maher and P. Black
A phase II study of prolonged daily
temozolomide for low-grade glioma
2005
ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1505.
Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement),
2005: 1522
|
|
|
Gliomatosis
Cerebri
|
|
|
|
|
Mattox AK, Lark AL, Adamson DC.
Marked
response of gliomatosis cerebri to temozolomide and whole brain radiotherapy.
Clin Neurol
Neurosurg. 2012 Feb 16. [Epub ahead of print]
Abstract |
Related articles
|
|
M.
Sanson, K. Djazouli, L. Djafari, M. Napolitano, H. Gervais, K. Hoang-Xuan,
K. Mokhtari, J. Cougnard, A. Hasbini, J.-Y. Delattre
Up-front chemotherapy temozolomide in the
treatment of Gliomatosis Cerebri: Analysis of 33 patients
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
458
|
|
|
Malignant
Lymphoma
|
|
|
|
B.
Evans, J. Quinn, D. Reardon, J. Rich, S. Gururangan, A. Friedman, R.
McLendon, S. Tourt-Uhlig, V. Stafford-Fox, H. S. Friedman
Phase II treatment of adults with newly diagnosed,
progressive or recurrent primary central nervous system lymphoma with
temozolomide
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
438
|
|
|
Kurzwelly
D, Glas M, Roth P, Weimann E, Lohner H, Waha A, Schabet M, Reifenberger G,
Weller M, Herrlinger U
Primary
CNS lymphoma in the elderly: temozolomide therapy and MGMT status
J
Neurooncol. 2010 May;97(3):389-92. Epub 2009 Oct 20
Abstract |
.png)
Full Text |
Reprint
|
|
|
Makino K, Nakamura H, Hide TI, Kuratsu JI.
Salvage
treatment with temozolomide in refractory or relapsed primary central
nervous system lymphoma and assessment of the MGMT status.
J Neurooncol.
2011 Jul 1. [Epub ahead of print]
Abstract |
Related articles
|
|
|
Omuro AM, Taillandier L, Chinot O, Carnin C,
Barrie M, Hoang-Xuan K.
Temozolomide and methotrexate for primary central nervous system lymphoma
in the elderly
J Neurooncol.
2007 Nov;85(2):207-11.
Epub 2007 Sep 21
Abstract
|
|
|
Metastatic
Tumors
|
|
|
|
Agarwala SS, Kirkwood JM, Gore M, Dreno B, Thatcher N,
Czarnetski B, Atkins M, Buzaid A, Skarlos D, Rankin EM
Temozolomide for the treatment of brain
metastases associated with metastatic melanoma: a phase II study
J Clin Oncol. 2004 Jun 1;22(11):2101-7.
|
|
M. Caraglia, R. Addeo, R.
Costanzo, L. Montella, V. Faiola, E. Capasso, S. Del Prete
Pegylated liposomal doxorubicin plus
temozolamide in the salvage treatment of brain metastases: The update
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No.1576
|
|
|
Chiarion-Sileni V, Guida M, Ridolfi L, Romanini A, Del Bianco P, Pigozzo J,
Brugnara S, Colucci G, Ridolfi R, De Salvo GL; Italian Melanoma Intergroup
(IMI).
Central
nervous system failure in melanoma patients: results of a randomised,
multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
Br J Cancer.
2011 Jun 7;104(12):1816-21. Epub 2011 May 24.
Abstract |
Reprint |
Related articles
|
|
|
Christos Christodoulou,
Dimitrios Bafaloukos, Helen Linardou,
Gerassimos Aravantinos, Aristotelis Bamias,
Maria Carina, George Klouvas and
Dimosthenis Skarlos
Temozolomide (TMZ) combined with cisplatin (CDDP) in patients with
brain metastases from solid tumors: a Hellenic Cooperative Oncology
Group (HeCOG) Phase II study
Journal
of Neuro-Oncology, 71(1):
61-65, January 2005. (Abstract+)
|
|
Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, Williams LJ,
Krown SE, Chapman PB, Livingston PO, Wolchok JD, Houghton AN
Temozolomide plus thalidomide in patients with brain
metastases from melanoma
Cancer.
2005 Apr 28; [Epub ahead of print]
|
|
|
Iwamoto
FM, Omuro AM, Raizer JJ, Nolan CP, Hormigo A, Lassman AB, Gavrilovic IT,
Abrey LE.
A phase II trial of vinorelbine
and intensive temozolomide for patients with recurrent or progressive brain
metastases.
J Neurooncol.
2007 Nov 7; [Epub ahead of print]
Abstract
|
|
|
Kouvaris
JR, Miliadou A, Kouloulias VE, Kolokouris D, Balafouta MJ, Papacharalampous
XN, Vlahos LJ.
Phase II Study of Temozolomide and Concomitant Whole-Brain Radiotherapy in
Patients with Brain Metastases from Solid Tumors.
Onkologie. 2007
Jul;30(7):361-6. Epub 2007 Jun 27.
PMID: 17596744 [PubMed - in process]
|
|
T.
H. Davis, C. E. Fadul, M. J. Glantz, L. L. Lewis, P. R. Bouchard, T. M.
Bator, J. L. Gonzalez, A. C. Mamourian, B. F. Cole
Pilot phase II trial of temozolomide for
leptomeningeal metastases: Preliminary report
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
460
|
|
S.
Del Prete, M. Caraglia, R. Addeo, R. Costanzo, V. Faiola, G. Facchini
Pegylated
liposomal doxorubicin plus temozolamide in the salvage treatment of brain
metastases: A feasibility study
39th ASCO Annual
Meeting. Chicago, IL. May 31-June 3, 2003.
|
|
H.
S. Friedman, B. Evans, D. Reardon, J. Quinn, J. Rich, S. Gururangan, V.
Stafford-Fox, C. Chen, A. Pati, W. Schmidt
Phase II trial of temozolomide for patients with
progressive brain metastases
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
408
|
|
Sewa S. Legha
Treatment of brain metastases from
melanoma
Journal of Clinical Oncology, Vol 23, No
13 (May 1), 2005: pp. 3155. (PDF
Full Text)
|
|
|
Mikkelsen
T, Anderson J, Doyle TJ, Croteau D, Avedissian R, Ryu S, Schultz L.
Phase I/II dose escalation trial of concurrent temozolomide and whole
brain radiation therapy for multiple brain metastasis
J Neurooncol. 2010 Apr 30;. [Epub ahead of print]
Abstract
|
|
A. M. P. Omuro, J. J. Raizer,
L. E. Abrey
A phase I trial of temozolomide and vinorelbine in
patients with recurrent brain metastases
40th
ASCO Annual Meeting. New Orleans, LA. June 5-8, 2004. Abstract No. 1567
|
|
S.
Siena, G. Landonio, E. Baietta, M. Vitali, L. Crino', M. Danova, A.
Musolino, G. Gardin, P. Foa, G. Fincato
Multicenter
phase II study of temozolomide therapy for brain metastasis in patients
with malignant melanoma, breast cancer, and non-small cell lung cancer
39th ASCO Annual
Meeting. Chicago, IL. May 31-June 3, 2003.
Abstract No. 407
|
|
E.
Verger, M. Gil, R. Yaya, N. Vinolas, S. Villa, T. Pujol, M. V. Solano,
L. Arribas, F. Graus
Concomitant
temozolomide (TMZ) and whole brain radiotherapy (WBRT) in patients with
brain metastases (BM): Randomized multicentric phase II study
39th ASCO Annual Meeting. Chicago, IL. May 31-June 3, 2003. Abstract No.
404
|
|
Eugenia
Verger, Miguel Gil, Ricardo Yaya, Nuria Vinolas, Salvador Villa,
Teresa Pujol, M Victoria Solano, Francesc Graus
Concomitant
temozolomide (TMZ) and radiotherapy (RT) in patients with brain
metastases: randomized multicentric phase II study, a preliminary report
38th
ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract No. 309
|
|
|
Weller
M.
Radiochemotherapy for brain metastasis: how to define a role for
temozolomide.
Onkologie. 2007
Jul;30(7):350-1. Epub 2007 Jun 27. No abstract available.
PMID: 17596741 [PubMed - in process]
|
|
Melanoma
|
|
|
|
Schild
SE, Behl
D, Markovic
SN, Brown
PD, Sande
JR, Deming
RL, Rowland
KM Jr, Bearden
JD
Brain
Metastases From Melanoma: Is There a Role for Concurrent Temozolomide in
Addition to Whole Brain Radiation Therapy?
Am
J Clin Oncol. 2009 Dec 30. [Epub ahead of print]
Abstract
|
|
|
Olfactory
Neuroblastoma
|
|
|
|
|
Wolfgang Wick, Antje Wick, Wilhelm Küker,
Johannes Dichgans, Michael Weller
Intracranial
Metastatic Esthesioneuroblastoma Responsive to Temozolomide
J
Neurooncol, 70(1):73-75, Oct. 2004.
(Abstract+)
|
|
|
Oligoastrocytic
Tumors
|
|
|
|
|
Ducray
F, del Rio MS, Carpentier C, Psimaras D, Idbaih A, Dehais C, Kaloshi G,
Mokhtari K, Taillibert S, Laigle-Donadey F, Omuro A, Sanson M, Delattre JY,
Hoang-Xuan K.
Up-front
temozolomide in elderly patients with anaplastic oligodendroglioma and
oligoastrocytoma.
J
Neurooncol. 2011 Feb;101(3):457-62. Epub
2010 Jun 17.
Abstract |
Reprint |
Related articles
|
|
|
Passarin
MG, Moretto G, Musso AM, Ottaviani S, Masotto B, Ghimenton C, Iuzzolino P,
Buffone E, Rudŕ R, Soffietti R, Vattemi E, Pedersini R
Intrathecal
liposomal cytarabine in combination with temozolomide in low-grade
oligoastrocytoma with leptomeningeal dissemination
J
Neurooncol. 2010 May;97(3):439-44. Epub 2009 Oct 31
Abstract |
Full Text |
Reprint
|
|
|
Oligodendroglial
Tumors
|
|
|
|
A.
A. Brandes, U. Basso, F. Vastola, L. M. Pasetto, S. Lonardi, A. Scola,
G. Ravenna, B. Coria, F. Chioffi, M. Ermani
First line chemotherapy with temozolomide (TMZ)
in recurrent or progressive oligodendroglioma
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
426
|
|
|
Thomas
N. Byrne
Response
of low-grade oligodendroglial tumors to temozolomide
Journal
of Neuro-Oncology, 70(3):
279-280, December 2004
|
|
|
Chinot
OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X,
Braguer D, Martin PM, Grisoli F.
Safety and efficacy of temozolomide in patients
with recurrent anaplastic oligodendrogliomas after standard radiotherapy
and chemotherapy
J Clin Oncol 2001 May 1;19(9):2449-55
|
|
H.
Kaur, L. Wood, D. Schiff, G. Barnett, M. Vogelbaum, G. Stevens, R.
Prayson, S. Staugaitis, P. Elson, D. Peereboom
Phase II multicenter study of 7/7 dosing of
temozolomide (TMZ) in patients (pts) with newly diagnosed pure and mixed
anaplastic oligodendroglioma (AO/MAO)
39th ASCO Annual Meeting.
Chicago, IL. May 31-June 3, 2003. Abstract No.
443
|
|
|
Mikkelsen
T, Doyle T, Anderson J, Margolis J, Paleologos N, Gutierrez J, Croteau D,
Hasselbach L, Avedissian R, Schultz L
Temozolomide
single-agent chemotherapy for newly diagnosed anaplastic oligodendroglioma
J Neurooncol.
2009 Mar;92(1):57-63. Epub 2008 Nov 15
Abstract
|
|
|
Netta Levin, M.D., Iris Lavon, Ph.D., R.A., Bracha
Zelikovitsh, Dana Fuchs, Bs.C., Felix Bokstein, M.D., Yakov Fellig, M.D., Tali
Siegal, M.D.
Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA
methyltransferase protein expression
Cancer, Volume 106, No 8 , Pages 1759 -
1765. Published Online: 15 Mar 2006
Abstract
|
|
Ozyigit
G, Onal
C, Gurkaynak
M, Soylemezoglu
F, Zorlu
F
Postoperative radiotherapy and chemotherapy in the
management of oligodendroglioma: single institutional review of 88 patients
J Neurooncol. 2005 Nov;75(2):189-93.
|
|
Martin
J van den Bent,
M J Taphoorn, A A Brandes, J Menten, R Stupp, M Frenay, C C van
der Rijt, J M Kros, A Allgeier, T Gorlia
EORTC
brain tumor group study 26971: first line chemotherapy with temozolomide in
recurrent oligodendroglial tumors; a phase II study
38th ASCO Annual Meeting. Orlando, FL. May 18-21, 2002.
Abstract
No.
285
|
|
M
J van den Bent, O Chinot, W Boogerd, J Bravo-Marques, MJB Taphoorn, JM Kros, CDD
van de Rijt, N de Beule, B Baron, On Behalf of the EORTC Brain Tumor Group.
EORTC
Study 26972: Second Line Temozolomide Chemotherapy in Recurrent Oligodendroglial
Tumors After PCV Chemotherapy: a Phase II Study
ASCO Proceedings, 2001 Annual Meeting, Abstract No. 203
|
|
|
Pituitary
Tumors
|
|
|
|
|
Mohammed
S, Kovacs K, Mason W, Smyth H, Cusimano MD
Use of temozolomide in aggressive pituitary tumors: case report
Neurosurgery. 2009 Apr;64(4):E773-4
Abstract
|
|
|
Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H,
Cusimano M, Kovacs K, Horvath E.
Treatment
of pituitary neoplasms with temozolomide: a review.
Cancer. 2011 Feb 1;117(3):454-62.
doi: 10.1002/cncr.25413. Epub 2010 Sep 15.
Abstract |
Related articles
|
|
